Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

Peter Gilling; Neil Barber; Mohamed Bidair; Paul Anderson; Mark Sutton; Tev Aho; Eugene Kramolowsky; Andrew Thomas; Barrett Cowan; Ronald P. Kaufman; Andrew Trainer; Andrew Arther; Gopal Badlani; Mark Plante; Mihir Desai; Leo Doumanian; Alexis E. Te; Mark DeGuenther; Claus Roehrborn

doi:10.1007/s12325-019-00952-3

Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

Peter Gilling, Neil Barber, Mohamed Bidair, Paul Anderson, Mark Sutton, Tev Aho, Eugene Kramolowsky, Andrew Thomas, Barrett Cowan, Ronald P. Kaufman, Andrew Trainer, Andrew Arther, Gopal Badlani, Mark Plante, Mihir Desai, Leo Doumanian, Alexis E. Te, Mark DeGuenther, Claus Roehrborn

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Introduction: To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). Methods: One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes. Results: At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (p =.8304, 95% CI for difference − 2.1 to 2.6 points). Two-year improvements in maximum flow rate (Q_max) were large in both groups at 11.2 and 8.6 cc/s for Aquablation and TURP, respectively (p = 0.1880, 95% CI for difference − 1.3 to 6.4). Sexual function as assessed by MSHQ was stable in the Aquablation group and decreased slightly in the TURP group. At 2 years, PSA was reduced significantly in both groups by 0.7 and 1.2 points, respectively; the reduction was similar across groups (p = 0.1816). Surgical retreatment rates after 12 months for Aquablation were 1.7% and 0% for TURP. Over 2 years, surgical BPH retreatment rates were 4.3% and 1.5% (p = 0.4219), respectively. Conclusion: Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP. Trial Registration: ClinicalTrials.gov no. NCT02505919. Funding: PROCEPT BioRobotics.

Original language	English (US)
Pages (from-to)	1326-1336
Number of pages	11
Journal	Advances in Therapy
Volume	36
Issue number	6
DOIs	https://doi.org/10.1007/s12325-019-00952-3
State	Published - Jun 1 2019

Keywords

Aquablation
BPH
Robotic surgery
TURP
Urology

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1007/s12325-019-00952-3

Cite this

Gilling, P., Barber, N., Bidair, M., Anderson, P., Sutton, M., Aho, T., Kramolowsky, E., Thomas, A., Cowan, B., Kaufman, R. P., Trainer, A., Arther, A., Badlani, G., Plante, M., Desai, M., Doumanian, L., Te, A. E., DeGuenther, M., & Roehrborn, C. (2019). Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained. Advances in Therapy, 36(6), 1326-1336. https://doi.org/10.1007/s12325-019-00952-3

Gilling, P, Barber, N, Bidair, M, Anderson, P, Sutton, M, Aho, T, Kramolowsky, E, Thomas, A, Cowan, B, Kaufman, RP, Trainer, A, Arther, A, Badlani, G, Plante, M, Desai, M, Doumanian, L, Te, AE, DeGuenther, M & Roehrborn, C 2019, 'Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained', Advances in Therapy, vol. 36, no. 6, pp. 1326-1336. https://doi.org/10.1007/s12325-019-00952-3

@article{9e997e089d0a470db2df5d820b5e526b,

title = "Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained",

abstract = "Introduction: To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). Methods: One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes. Results: At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (p =.8304, 95% CI for difference − 2.1 to 2.6 points). Two-year improvements in maximum flow rate (Qmax) were large in both groups at 11.2 and 8.6 cc/s for Aquablation and TURP, respectively (p = 0.1880, 95% CI for difference − 1.3 to 6.4). Sexual function as assessed by MSHQ was stable in the Aquablation group and decreased slightly in the TURP group. At 2 years, PSA was reduced significantly in both groups by 0.7 and 1.2 points, respectively; the reduction was similar across groups (p = 0.1816). Surgical retreatment rates after 12 months for Aquablation were 1.7% and 0% for TURP. Over 2 years, surgical BPH retreatment rates were 4.3% and 1.5% (p = 0.4219), respectively. Conclusion: Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP. Trial Registration: ClinicalTrials.gov no. NCT02505919. Funding: PROCEPT BioRobotics.",

keywords = "Aquablation, BPH, Robotic surgery, TURP, Urology",

author = "Peter Gilling and Neil Barber and Mohamed Bidair and Paul Anderson and Mark Sutton and Tev Aho and Eugene Kramolowsky and Andrew Thomas and Barrett Cowan and Kaufman, {Ronald P.} and Andrew Trainer and Andrew Arther and Gopal Badlani and Mark Plante and Mihir Desai and Leo Doumanian and Te, {Alexis E.} and Mark DeGuenther and Claus Roehrborn",

note = "Publisher Copyright: {\textcopyright} 2019, The Author(s).",

year = "2019",

month = jun,

day = "1",

doi = "10.1007/s12325-019-00952-3",

language = "English (US)",

volume = "36",

pages = "1326--1336",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Health Communications Inc.",

number = "6",

}

TY - JOUR

T1 - Two-Year Outcomes After Aquablation Compared to TURP

T2 - Efficacy and Ejaculatory Improvements Sustained

AU - Gilling, Peter

AU - Barber, Neil

AU - Bidair, Mohamed

AU - Anderson, Paul

AU - Sutton, Mark

AU - Aho, Tev

AU - Kramolowsky, Eugene

AU - Thomas, Andrew

AU - Cowan, Barrett

AU - Kaufman, Ronald P.

AU - Trainer, Andrew

AU - Arther, Andrew

AU - Badlani, Gopal

AU - Plante, Mark

AU - Desai, Mihir

AU - Doumanian, Leo

AU - Te, Alexis E.

AU - DeGuenther, Mark

AU - Roehrborn, Claus

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Introduction: To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). Methods: One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes. Results: At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (p =.8304, 95% CI for difference − 2.1 to 2.6 points). Two-year improvements in maximum flow rate (Qmax) were large in both groups at 11.2 and 8.6 cc/s for Aquablation and TURP, respectively (p = 0.1880, 95% CI for difference − 1.3 to 6.4). Sexual function as assessed by MSHQ was stable in the Aquablation group and decreased slightly in the TURP group. At 2 years, PSA was reduced significantly in both groups by 0.7 and 1.2 points, respectively; the reduction was similar across groups (p = 0.1816). Surgical retreatment rates after 12 months for Aquablation were 1.7% and 0% for TURP. Over 2 years, surgical BPH retreatment rates were 4.3% and 1.5% (p = 0.4219), respectively. Conclusion: Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP. Trial Registration: ClinicalTrials.gov no. NCT02505919. Funding: PROCEPT BioRobotics.

AB - Introduction: To compare 2-year safety and efficacy outcomes after Aquablation or transurethral resection of the prostate (TURP) for the treatment of lower urinary tract symptoms related to benign prostate hyperplasia (BPH). Methods: One hundred eighty-one patients with BPH were assigned at random (2:1 ratio) to either Aquablation or TURP. Patients and follow-up assessors were blinded to treatment. Assessments included the International Prostate Symptom Score (IPSS), Male Sexual Health Questionnaire (MSHQ), International Index of Erectile Function and uroflow. The focus of analysis was 2-year outcomes. Results: At 2 years, IPSS scores improved by 14.7 points in the Aquablation group and 14.9 points in TURP (p =.8304, 95% CI for difference − 2.1 to 2.6 points). Two-year improvements in maximum flow rate (Qmax) were large in both groups at 11.2 and 8.6 cc/s for Aquablation and TURP, respectively (p = 0.1880, 95% CI for difference − 1.3 to 6.4). Sexual function as assessed by MSHQ was stable in the Aquablation group and decreased slightly in the TURP group. At 2 years, PSA was reduced significantly in both groups by 0.7 and 1.2 points, respectively; the reduction was similar across groups (p = 0.1816). Surgical retreatment rates after 12 months for Aquablation were 1.7% and 0% for TURP. Over 2 years, surgical BPH retreatment rates were 4.3% and 1.5% (p = 0.4219), respectively. Conclusion: Two-year efficacy outcomes after TURP and Aquablation were similar, and the rate of surgical retreatment was low and similar to TURP. Trial Registration: ClinicalTrials.gov no. NCT02505919. Funding: PROCEPT BioRobotics.

KW - Aquablation

KW - BPH

KW - Robotic surgery

KW - TURP

KW - Urology

UR - http://www.scopus.com/inward/record.url?scp=85065042923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065042923&partnerID=8YFLogxK

U2 - 10.1007/s12325-019-00952-3

DO - 10.1007/s12325-019-00952-3

M3 - Article

C2 - 31028614

AN - SCOPUS:85065042923

SN - 0741-238X

VL - 36

SP - 1326

EP - 1336

JO - Advances in Therapy

JF - Advances in Therapy

IS - 6

ER -

Two-Year Outcomes After Aquablation Compared to TURP: Efficacy and Ejaculatory Improvements Sustained

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this